COMPANY PROFILE

Micell Technologies

Explore full profile

Biomedical device company developing interventional cardiology systems for vascular drug delivery

Durham, United StatesFounded 1995Biotech & Life Sciences

Valuation $100–250M Last recorded · 2017

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Micell Technologies

Micell Technologies specializes in developing advanced medical devices aimed at improving patient outcomes, particularly in the field of interventional cardiology. The company's proprietary technology utilizes supercritical fluids to enable prolonged therapeutic drug dosing after polymer absorption. This technology is primarily applied in their bioabsorbable polymer stents, which are designed to provide controlled and sustained drug elution in tissue, thereby enhancing clinical results. Micell's products are available through key distribution partners and are currently accessible in select countries worldwide. The company conducts ongoing clinical trials to validate the effectiveness of their technology, ensuring that their products meet rigorous medical standards. Micell Technologies serves healthcare providers and medical institutions that require cutting-edge solutions for cardiovascular treatments. The business operates in the medical device market, generating revenue through the sale of its specialized stents and related technologies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 1995
Headquarters: Durham, United States
Employees: 9
Open positions: None listed
Dealroom signal: 58.4/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Sep 2017	$62M	$247M	SIP (Strategic Investment Partners Ltd.) · Five Points Capital · Gladwyne Partners	—
SEEDOther financing	Dec 2009	$300K	$1.2M	Five Points Capital · SIP (Strategic Investment Partners Ltd.) · Gladwyne Partners	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Micell Technologies website traffic

Latest recorded traffic for Micell Technologies is 30 monthly website visits, down 76.9% over the last three months. Micell Technologies's team grew 0% over the past year.

Latest monthly visits30 3-month web change-76.9% 1-year team growth0%

Monthly website visitsOct 2017–Sep 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CACardioMEMSWireless sensing and communication technology solutions for severe chronic cardiovascular diseases in the human body	Atlanta, United States	Acquired	39	$231M	$455M
MEMedisieveMagnetic blood filtration enhancing gene therapy efficacy.	London, United Kingdom	Operational
COCollplantRegenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing	Ness Ziona, Israel	Operational
TITiGenixLocal treatments for damaged and osteoarthritic joints	Leuven, Belgium	Acquired
NTNeograft TechnologiesNeograft Technologies – Advanced technology for coronary artery bypass graft surgery	Taunton, United States	Operational
ETECM TherapeuticsRestoring health and functional tissues with extracellular matrix-based signaling molecules	Marshall Township, United States	Operational
FBFreeOx BiotechAdvancing Stroke Care through Innovation and Precision Medicine	Barcelona, Spain	Operational
APAderis PharmaceuticalsAderis Pharmaceuticals focused on discovery, development and commercialization of products for the diagnosis	Hopkinton, United States	Acquired